RE:RE:RE:Big Pharma has compelling valuations & ‘ROOM to RUN’longrun86 wrote: It would appear that Endo has double-downed on the same hubris that brought it to its present condition.
It is shocking for them to say that they do not have a "Liquidity Issue".
There will be opportunities for Knight; however, I am somewhat concerned about how the current market conditions will impact the fund investments and the eventual cash realization.
While the Healthcare sector is strong and less volatile by cyclicality, the overall changes to capital access and pricing will drive valuations lower.
It's really a battle between debtors who want to get paid now vs. controlling debtors who want ENDO to miss the present debt payments and focus on overall restructuring.
Not exactly sure how you restructure when you are facing unknown debts on the opioid side. Need to get that part figured out quickly so that restructuring discussions have meaning. Endo is total junk IMO.
GUD needs to grow operations quickly to overshadow the investment side. I'm assuming that's the goal anyway from this point forward - but - they won't rush it until they have drugs/businesses to purchase that fit their strategy. It's coming ... we just don't know "when."